Noninvasive MASH Diagnostic Tests Market Size, Trend, Forecast Report 2026 to 2035
Segmentations Noninvasive MASH Diagnostic Tests Market:
Noninvasive MASH Diagnostic Tests Market by Test Modality -
- Blood-Based Biomarker Tests
- Proprietary Multi-Analyte Algorithmic Panels
- Defined-Biomarker IVD Assays
- Ultrasound-Based Tests
- Vibration-Controlled Transient Elastography
- 2D Shear-Wave & Quantitative Ultrasound
- MRI-Based Tests
- Magnetic Resonance Elastography
- Multiparametric & Quantitative MRI
- Routine-Data Algorithmic Tests
Noninvasive MASH Diagnostic Tests Market by Clinical Application / Intended Use -
- Steatosis Detection & Quantification
- At-Risk (Fibrotic) MASH Identification
- Fibrosis Staging
- Disease Monitoring & Treatment
- Prognosis & Risk Stratification
- Clinical-Trial Enrichment & Surrogate Endpoints
Noninvasive MASH Diagnostic Tests Market by Regulatory / Commercialisation Pathway-
- Laboratory-Developed Tests
- FDA-Cleared / Authorised IVDs
- CE-Marked IVDs
- Software as a Medical Device
Noninvasive MASH Diagnostic Tests Market by End User -
- Hospitals & Hepatology / Gastroenterology Specialty Clinics
- Diagnostic & Reference Laboratories
- Primary Care & Point-of-Care Settings
- Imaging & Diagnostic Centres
- Pharmaceutical & CRO
Noninvasive MASH Diagnostic Tests Market by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Noninvasive MASH Diagnostic Tests Market Snapshot
Chapter 4. Global Noninvasive MASH Diagnostic Tests Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Market Trends
4.5. Regulatory and Diagnostic Testing Landscape
4.6. Porter’s Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ Mn), 2025–2035
4.8. Market Penetration & Growth Prospect Mapping (US$ Mn), 2026–2035
4.9. Competitive Landscape & Market Share Analysis, 2026
4.10. Impact of Rising MASH Disease Prevalence, Noninvasive Diagnostic Adoption, Biomarker Innovation, and Emerging MASH Therapeutics on the Noninvasive MASH Diagnostic Tests Market
Chapter 5. Noninvasive MASH Diagnostic Tests Market Segmentation: By Test Modality
5.1. Market Share, 2025 & 2035
5.2. Market Size (US$ Mn), 2022–2035
5.2.1. Blood-Based Biomarker Tests
5.2.1.1. Proprietary Multi-Analyte Algorithmic Panels
5.2.1.2. Defined-Biomarker IVD Assays
5.2.2. Ultrasound-Based Tests
5.2.2.1. Vibration-Controlled Transient Elastography
5.2.2.2. 2D Shear-Wave & Quantitative Ultrasound
5.2.3. MRI-Based Tests
5.2.3.1. Magnetic Resonance Elastography
5.2.3.2. Multiparametric & Quantitative MRI
5.2.4. Routine-Data Algorithmic Tests
Chapter 6. Noninvasive MASH Diagnostic Tests Market Segmentation: By Clinical Application / Intended Use
6.1. Market Share, 2025 & 2035
6.2. Market Size (US$ Mn), 2022–2035
6.2.1. Steatosis Detection & Quantification
6.2.2. At-Risk (Fibrotic) MASH Identification
6.2.3. Fibrosis Staging
6.2.4. Disease Monitoring & Treatment
6.2.5. Prognosis & Risk Stratification
6.2.6. Clinical-Trial Enrichment & Surrogate Endpoints
Chapter 7. Noninvasive MASH Diagnostic Tests Market Segmentation: By Regulatory / Commercialisation Pathway
7.1. Market Share, 2025 & 2035
7.2. Market Size (US$ Mn), 2022–2035
7.2.1. Laboratory-Developed Tests
7.2.2. FDA-Cleared / Authorised IVDs
7.2.3. CE-Marked IVDs
7.2.4. Software as a Medical Device
Chapter 8. Noninvasive MASH Diagnostic Tests Market Segmentation: By End User
8.1. Market Share, 2025 & 2035
8.2. Market Size (US$ Mn), 2022–2035
8.2.1. Hospitals & Hepatology / Gastroenterology Specialty Clinics
8.2.2. Diagnostic & Reference Laboratories
8.2.3. Primary Care & Point-of-Care Settings
8.2.4. Imaging & Diagnostic Centres
8.2.5. Pharmaceutical & CRO
Chapter 9. Regional Noninvasive MASH Diagnostic Tests Market Estimates & Trend Analysis
9.1. Global Market Regional Snapshot, 2025 & 2035
9.2. North America
9.2.1. Market Revenue by Country (U.S., Canada, Mexico), 2022–2035
9.2.2. North America Noninvasive MASH Diagnostic Tests Market Revenue by Test Modality, 2022–2035
9.2.3. North America Noninvasive MASH Diagnostic Tests Market Revenue by Clinical Application / Intended Use, 2022–2035
9.2.4. North America Noninvasive MASH Diagnostic Tests Market Revenue by Regulatory / Commercialisation Pathway, 2022–2035
9.2.5. North America Noninvasive MASH Diagnostic Tests Market Revenue by End User, 2022–2035
9.3. Europe
9.3.1. Market Revenue by Country, 2022–2035
9.3.2. Europe Noninvasive MASH Diagnostic Tests Market Revenue by Test Modality, 2022–2035
9.3.3. Europe Noninvasive MASH Diagnostic Tests Market Revenue by Clinical Application / Intended Use, 2022–2035
9.3.4. Europe Noninvasive MASH Diagnostic Tests Market Revenue by Regulatory / Commercialisation Pathway, 2022–2035
9.3.5. Europe Noninvasive MASH Diagnostic Tests Market Revenue by End User, 2022–2035
9.4. Asia Pacific
9.4.1. Market Revenue by Country, 2022–2035
9.4.2. Asia Pacific Noninvasive MASH Diagnostic Tests Market Revenue by Test Modality, 2022–2035
9.4.3. Asia Pacific Noninvasive MASH Diagnostic Tests Market Revenue by Clinical Application / Intended Use, 2022–2035
9.4.4. Asia Pacific Noninvasive MASH Diagnostic Tests Market Revenue by Regulatory / Commercialisation Pathway, 2022–2035
9.4.5. Asia Pacific Noninvasive MASH Diagnostic Tests Market Revenue by End User, 2022–2035
9.5. Latin America
9.5.1. Market Revenue by Country, 2022–2035
9.5.2. Latin America Noninvasive MASH Diagnostic Tests Market Revenue by Test Modality, 2022–2035
9.5.3. Latin America Noninvasive MASH Diagnostic Tests Market Revenue by Clinical Application / Intended Use, 2022–2035
9.5.4. Latin America Noninvasive MASH Diagnostic Tests Market Revenue by Regulatory / Commercialisation Pathway, 2022–2035
9.5.5. Latin America Noninvasive MASH Diagnostic Tests Market Revenue by End User, 2022–2035
9.6. Middle East & Africa
9.6.1. Market Revenue by Country, 2022–2035
9.6.2. Middle East & Africa Noninvasive MASH Diagnostic Tests Market Revenue by Test Modality, 2022–2035
9.6.3. Middle East & Africa Noninvasive MASH Diagnostic Tests Market Revenue by Clinical Application / Intended Use, 2022–2035
9.6.4. Middle East & Africa Noninvasive MASH Diagnostic Tests Market Revenue by Regulatory / Commercialisation Pathway, 2022–2035
9.6.5. Middle East & Africa Noninvasive MASH Diagnostic Tests Market Revenue by End User, 2022–2035
Chapter 10. Competitive Landscape
10.1. Key Strategic Developments (Partnerships, Acquisitions, Product Launches, Regulatory Approvals, Clinical Validations, and Technology Investments)
10.2. Market Share Analysis, 2026
10.3. Company Profiles
10.3.1. Blood-Based Biomarker & Algorithmic Test Developers
10.3.1.1. GENFIT S.A.
10.3.1.2. Prometheus Laboratories Inc.
10.3.1.3. BioPredictive
10.3.1.4. Nordic Bioscience
10.3.1.5. Fibronostics
10.3.1.6. Rubió Metabolomics / CIMA Sciences (OWLiver)
10.3.1.7. Hepta (cfDNA Methylation + AI)
10.3.1.8. PathAI
10.3.1.9. Proteomic & Multi-Omic MASH Signatures
10.3.2. Elastography & Ultrasound-Based Diagnostic Technology Providers
10.3.2.1. Echosens
10.3.2.2. Siemens Healthineers
10.3.2.3. Canon Medical Systems
10.3.2.4. Sonic Incytes Medical Corp.
10.3.2.5. E-Scopics
10.3.2.6. Wuxi Hisky Medical Technologies
10.3.2.7. Mindray Medical
10.3.2.8. GE HealthCare
10.3.2.9. Philips
10.3.2.10. Samsung Medison
10.3.3. MRI-Based Diagnostic Technology Providers
10.3.3.1. Perspectum Ltd.
10.3.3.2. Resoundant, Inc.
10.3.3.3. Resonance Health Ltd.
10.3.3.4. Siemens Healthineers
10.3.3.5. Canon Medical Systems
10.3.4. Diagnostic Laboratories & Testing Service Providers
10.3.4.1. Laboratory Corporation of America (Labcorp)
10.3.4.2. Roche Diagnostics
10.3.4.3. Quest Diagnostics
10.3.5. Emerging AI/ML & Digital Diagnostic Solution Developers
10.3.5.1. Academic-Origin AI/ML Fibrosis Algorithms in Commercialisation
10.3.5.2. HistoIndex
10.3.5.3. PathAI
10.3.6. Pharmaceutical Companies & Clinical Development Stakeholders
10.3.6.1. Madrigal Pharmaceuticals
10.3.6.2. Novo Nordisk
10.3.6.3. Eli Lilly
10.3.6.4. Boehringer Ingelheim
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Noninvasive MASH Diagnostic Tests Market is estimated to grow at a 16.0% CAGR during the forecast period for 2026 to 2035.
Echosens, Siemens Healthineers, Laboratory Corporation of America (Labcorp), Roche Diagnostics, GENFIT S.A., Perspectum Ltd., Resoundant, Inc., Prometheus Laboratories Inc., BioPredictive, Nordic Bioscience, Quest Diagnostics, Fibronostics, Rubió Metabolomics / CIMA Sciences (OWLiver), Canon Medical Systems, Sonic Incytes Medical Corp., E-Scopics, Resonance Health Ltd., Hepta (cfDNA Methylation + AI), Wuxi Hisky Medical Technologies, Mindray Medical, Proteomic & Multi-Omic MASH Signatures, Academic-Origin AI/ML Fibrosis Algorithms in Commercialisation, GE HealthCare, Philips, Samsung Medison, HistoIndex, PathAI, Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Other.
Noninvasive MASH Diagnostic Tests Market is segmented into Test Modality,Clinical Application / Intended Use, Regulatory / Commercialisation Pathway, End User and Other.
North America region is leading the Noninvasive MASH Diagnostic Tests Market.
